Dupilumab is a highly efective biologic therapy that blocks the alpha subunit of interleukin 4 receptor (IL-4Rα) and disrupts T-helper 2-mediated inflammation in atopic dermatitis (AD) [1, 2]. The gene discussed is IL4R; the disease is atopic eczema.